Siddharth Singh1, Alina M Allen1, Zhen Wang2, Larry J Prokop2, Mohammad H Murad2, Rohit Loomba3. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 2. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota. 3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of California, San Diego, California. Electronic address: roloomba@ucsd.edu.
Abstract
BACKGROUND & AIMS: Little is known about differences in rates of fibrosis progression between patients with nonalcoholic fatty liver (NAFL) vs nonalcoholic steatohepatitis (NASH). We conducted a systematic review and meta-analysis of all studies that assessed paired liver biopsy specimens to estimate the rates of fibrosis progression in patients with nonalcoholic fatty liver disease (NAFLD) including NAFL and NASH. METHODS: Through a systematic search of multiple databases and author contact, up to June 2013, we identified studies of adults with NAFLD that collected paired liver biopsy specimens at least 1 year apart. From these, we calculated a pooled-weighted annual fibrosis progression rate (number of stages changed between the 2 biopsy samples) with 95% confidence intervals (CIs), and identified clinical risk factors associated with progression. RESULTS: We identified 11 cohort studies including 411 patients with biopsy-proven NAFLD (150 with NAFL and 261 with NASH). At baseline, the distribution of fibrosis for stages 0, 1, 2, 3, and 4 was 35.8%, 32.5%, 16.7%, 9.3%, and 5.7%, respectively. Over 2145.5 person-years of follow-up evaluation, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had an improvement in fibrosis stage. The annual fibrosis progression rate in patients with NAFL who had stage 0 fibrosis at baseline was 0.07 stages (95% CI, 0.02-0.11 stages), compared with 0.14 stages in patients with NASH (95% CI, 0.07-0.21 stages). These findings correspond to 1 stage of progression over 14.3 years for patients with NAFL (95% CI, 9.1-50.0 y) and 7.1 years for patients with NASH (95% CI, 4.8-14.3 y). CONCLUSIONS: Based on a meta-analysis of studies of paired liver biopsy studies, liver fibrosis progresses in patients with NAFL and NASH.
BACKGROUND & AIMS: Little is known about differences in rates of fibrosis progression between patients with nonalcoholic fatty liver (NAFL) vs nonalcoholic steatohepatitis (NASH). We conducted a systematic review and meta-analysis of all studies that assessed paired liver biopsy specimens to estimate the rates of fibrosis progression in patients with nonalcoholic fatty liver disease (NAFLD) including NAFL and NASH. METHODS: Through a systematic search of multiple databases and author contact, up to June 2013, we identified studies of adults with NAFLD that collected paired liver biopsy specimens at least 1 year apart. From these, we calculated a pooled-weighted annual fibrosis progression rate (number of stages changed between the 2 biopsy samples) with 95% confidence intervals (CIs), and identified clinical risk factors associated with progression. RESULTS: We identified 11 cohort studies including 411 patients with biopsy-proven NAFLD (150 with NAFL and 261 with NASH). At baseline, the distribution of fibrosis for stages 0, 1, 2, 3, and 4 was 35.8%, 32.5%, 16.7%, 9.3%, and 5.7%, respectively. Over 2145.5 person-years of follow-up evaluation, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had an improvement in fibrosis stage. The annual fibrosis progression rate in patients with NAFL who had stage 0 fibrosis at baseline was 0.07 stages (95% CI, 0.02-0.11 stages), compared with 0.14 stages in patients with NASH (95% CI, 0.07-0.21 stages). These findings correspond to 1 stage of progression over 14.3 years for patients with NAFL (95% CI, 9.1-50.0 y) and 7.1 years for patients with NASH (95% CI, 4.8-14.3 y). CONCLUSIONS: Based on a meta-analysis of studies of paired liver biopsy studies, liver fibrosis progresses in patients with NAFL and NASH.
Authors: V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard Journal: Gastroenterology Date: 2000-06 Impact factor: 22.682
Authors: Leon A Adams; Scott Harmsen; Jennifer L St Sauver; Phunchai Charatcharoenwitthaya; Felicity B Enders; Terry Therneau; Paul Angulo Journal: Am J Gastroenterol Date: 2010-02-09 Impact factor: 10.864
Authors: Alexander Wree; Lori Broderick; Ali Canbay; Hal M Hoffman; Ariel E Feldstein Journal: Nat Rev Gastroenterol Hepatol Date: 2013-08-20 Impact factor: 46.802
Authors: Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass Journal: Hepatology Date: 2012-07-26 Impact factor: 17.425
Authors: Etienne Patin; Zoltán Kutalik; Julien Guergnon; Stéphanie Bibert; Bertrand Nalpas; Emmanuelle Jouanguy; Mona Munteanu; Laurence Bousquet; Laurent Argiro; Philippe Halfon; Anne Boland; Beat Müllhaupt; David Semela; Jean-François Dufour; Markus H Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Hans Hirsch; Gladys Martinetti; Vijayaprakash Suppiah; Graeme Stewart; David R Booth; Jacob George; Jean-Laurent Casanova; Christian Bréchot; Charles M Rice; Andrew H Talal; Ira M Jacobson; Marc Bourlière; Ioannis Theodorou; Thierry Poynard; Francesco Negro; Stanislas Pol; Pierre-Yves Bochud; Laurent Abel Journal: Gastroenterology Date: 2012-07-27 Impact factor: 22.682
Authors: Mazen Noureddin; Katherine P Yates; Ivana A Vaughn; Brent A Neuschwander-Tetri; Arun J Sanyal; Arthur McCullough; Raphael Merriman; Bilal Hameed; Edward Doo; David E Kleiner; Cynthia Behling; Rohit Loomba Journal: Hepatology Date: 2013-10-02 Impact factor: 17.425
Authors: Manal F Abdelmalek; Schuyler O Sanderson; Paul Angulo; Consuelo Soldevila-Pico; Chen Liu; Joy Peter; Jill Keach; Matt Cave; Theresa Chen; Craig J McClain; Keith D Lindor Journal: Hepatology Date: 2009-12 Impact factor: 17.425
Authors: Geraldine J Ooi; Paul R Burton; Arul Earnest; Cheryl Laurie; William W Kemp; Peter D Nottle; Catriona A McLean; Stuart K Roberts; Wendy A Brown Journal: Obes Surg Date: 2018-02 Impact factor: 4.129
Authors: Rohit Loomba; Nicholas Schork; Chi-Hua Chen; Ricki Bettencourt; Ana Bhatt; Brandon Ang; Phirum Nguyen; Carolyn Hernandez; Lisa Richards; Joanie Salotti; Steven Lin; Ekihiro Seki; Karen E Nelson; Claude B Sirlin; David Brenner Journal: Gastroenterology Date: 2015-08-20 Impact factor: 22.682